DeDora Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.81M | Buy |
15,149
+450
| +3% | +$96.8K | 0.83% | 33 |
|
|
2026
Q1 | $3.2M | Sell |
14,699
-157
| -1% | -$34.8K | 0.78% | 33 |
|
|
2025
Q4 | $3.39M | Sell |
14,856
-398
| -3% | -$90.7K | 0.8% | 33 |
|
|
2025
Q3 | $3.53M | Sell |
15,254
-495
| -3% | -$101K | 0.85% | 30 |
|
|
2025
Q2 | $2.92M | Sell |
15,749
-162
| -1% | -$30.1K | 0.76% | 32 |
|
|
2025
Q1 | $3.33M | Sell |
15,911
-206
| -1% | -$40K | 0.96% | 27 |
|
|
2024
Q4 | $2.86M | Sell |
16,117
-63
| -0.4% | -$11.6K | 0.78% | 30 |
|
|
2024
Q3 | $3.2M | Sell |
16,180
-61
| -0.4% | -$11.4K | 0.89% | 28 |
|
|
2024
Q2 | $2.79M | Buy |
16,241
+283
| +2% | +$46.9K | 0.86% | 27 |
|
|
2024
Q1 | $2.91M | Sell |
15,958
-2,174
| -12% | -$375K | 0.93% | 27 |
|
|
2023
Q4 | $2.81M | Sell |
18,132
-674
| -4% | -$98.3K | 0.99% | 25 |
|
|
2023
Q3 | $2.8M | Buy |
18,806
+898
| +5% | +$132K | 1.1% | 24 |
|
|
2023
Q2 | $2.41M | Buy |
17,908
+677
| +4% | +$99.3K | 0.94% | 26 |
|
|
2023
Q1 | $2.75M | Buy |
17,231
+1,603
| +10% | +$245K | 1.17% | 22 |
|
|
2022
Q4 | $2.53M | Buy |
15,628
+38
| +0.2% | +$5.83K | 1.2% | 21 |
|
|
2022
Q3 | $2.09M | Buy |
15,590
+68
| +0.4% | +$9.76K | 1.09% | 20 |
|
|
2022
Q2 | $2.38M | Sell |
15,522
-1,038
| -6% | -$159K | 1.2% | 20 |
|
|
2022
Q1 | $2.68M | Buy |
+16,560
| New | +$2.41M | 1.08% | 20 |
|
|
2021
Q4 | – | Sell |
-16,636
| Closed | -$1.79M | – | 57 |
|
|
2021
Q3 | $1.79M | Buy |
16,636
+142
| +0.9% | +$16.2K | 0.78% | 30 |
|
|
2021
Q2 | $1.86M | Buy |
16,494
+260
| +2% | +$29.3K | 0.81% | 29 |
|
|
2021
Q1 | $1.76M | Sell |
16,234
-1,348
| -8% | -$144K | 0.83% | 28 |
|
|
2020
Q4 | $1.88M | Sell |
17,582
-1,728
| -9% | -$166K | 0.93% | 27 |
|
|
2020
Q3 | $1.69M | Buy |
19,310
+3,186
| +20% | +$300K | 0.94% | 27 |
|
|
2020
Q2 | $1.58M | Buy |
16,124
+748
| +5% | +$65.9K | 0.95% | 26 |
|
|
2020
Q1 | $1.17M | Buy |
15,376
+107
| +0.7% | +$9.11K | 0.88% | 31 |
|
|
2019
Q4 | $1.35M | Sell |
15,269
-816
| -5% | -$67.7K | 0.81% | 33 |
|
|
2019
Q3 | $1.22M | Sell |
16,085
-5,943
| -27% | -$407K | 0.84% | 34 |
|
|
2019
Q2 | $1.6M | Sell |
22,028
-6,250
| -22% | -$491K | 1.13% | 18 |
|
|
2019
Q1 | $2.28M | Buy |
28,278
+3,153
| +13% | +$258K | 1.72% | 12 |
|
|
2018
Q4 | $2.32M | Buy |
25,125
+395
| +2% | +$34.7K | 2.05% | 9 |
|
|
2018
Q3 | $2.34M | Buy |
24,730
+4,000
| +19% | +$379K | 1.77% | 12 |
|
|
2018
Q2 | $1.92M | Buy |
20,730
+76
| +0.4% | +$7.42K | 1.51% | 12 |
|
|
2018
Q1 | $1.96M | Buy |
20,654
+2,415
| +13% | +$265K | 1.59% | 13 |
|
|
2017
Q4 | $1.76M | Buy |
+18,239
| New | +$1.72M | 1.46% | 16 |
|
Other funds holding ABBV
DeDora Capital's ABBV Position: Q2 2026 in Review
DeDora Capital increased its AbbVie (ABBV) stake by 3.1% in Q2 2026, buying an estimated $96.8K and bringing the position to 15,149 shares worth $3.81M. The position accounts for 0.83% of the portfolio, ranked #33.
DeDora Capital first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- DeDora Capital held 15,149 shares of AbbVie worth $3.81M as of Q2 2026.
- DeDora Capital bought 450 AbbVie shares in Q2 2026, an estimated $96.8K.
- AbbVie made up 0.83% of DeDora Capital's portfolio in Q2 2026, its #33 holding.
- DeDora Capital first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on DeDora Capital's 13F filing for Q2 2026, filed 13 Jul 2026.